This content is intended for healthcare professionals only.

Please confirm that you are an EU healthcare professional.


This promotional activity has been sponsored by Jazz Pharmaceuticals. Jazz Pharmaceuticals provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Prescribing Information

Leukaemia View Time: 21 mins

touchSYMPOSIUM HIGHLIGHTS Treating high-risk* acute myeloid leukemia in the real world

Watch leading experts present and discuss real-world evidence on the use of Vyxeos® Liposomal (Daunorubicin 44mg / Cytarabine 100mg) for the treatment of high-risk* acute myeloid leukemia.
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

  • Symposium Presentations
The foundation: results for a pivotal Phase 3 trial in high-risk* AML
Latest real-world evidence on treating high-risk* AML in France and Italy
How might this real-world evidence impact the management of high-risk* AML?

Prof Hartmut Döhner
Ulm University Hospital, Germany read more

Hartmut Döhner is a Professor of Medicine and has been Medical Director of the Department of Internal Medicine III at Ulm University Hospital since 1999. He is a founding Director of the Comprehensive Cancer Center in Ulm and has been Coordinating Investigator of the Collaborative Research Center SFB 1074 “Experimental Models and Clinical Translation in Leukemia” since 2012.

Prof Arnaud Pigneux
Bordeaux University Hospital, France

Arnaud Pigneux is Professor at the Department of Clinical Hematology and Cell Therapy, Bordeaux University Hospital, France, and is part of the INSERM U1035 “Normal and Leukemic Stem Cells” team at the University of Bordeaux, France.

Prof Roberto M. Lemoli
San Martino Jospital, Genoa, Italy

Roberto Lemoli is Professor of Hematology at the University of Genoa, Italy and Director of the Clinic of Hematology at San Martino Hospital, Genoa. He is a member of several societies of hematology and served as President of the Italian Society of Experimental Hematology (SIES) from 2012 to 2014.


Prof Döhner: Research support/advisory boards for Abbvie, Agios, Amgen, Astellas, Astex, AstraZeneca, Berlin-Chemie, BMS, Celgene, GEMoaB, Gilead, Helsinn, Janssen, Jazz Pharmaceuticals, Novartis, Oxford Biomedica, Roche.

Prof Pigneux: Consultant/grant/research support/speaker fees from AbbVie, Agios, Astellas, BMS, Gilead, Jazz Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi, Takeda.

Prof Lemoli: Research funding/advisory role for AbbVie, Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis, Servier.

Leave Feedback
Learning Objectives & Overview

High-risk* acute myeloid leukemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, recorded at the 4th Annual Meeting of the International Academy of Clinical Hematology, four leading experts present and discuss the latest real-world evidence on the use of Vyxeos Liposomal (daunorubicin 44mg / cytarabine 100mg powder for concentrate for solution for infusion) for the treatment of high-risk* AML, and how this might change the management of the condition.2–4

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Video content supplied by Jazz Pharmaceuticals

Learning Objectives

After watching this activity, participants should be better able to:

  • Discuss the diagnosis and prognosis of high-risk* AML
  • Review the clinical and real-world evidence on the use of Vyxeos® Liposomal for the treatment of high-risk* AML
  • Discuss the impact this real-world evidence may have on the management of high-risk* AML

*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Adverse Events
Adverse Events

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to

  1. Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
  2. Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
  3. Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
  4. Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.

View and download resources from this activity to support your learning.

Feedback Close

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72